Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

BeiGene Approved to Launch Bi-Specific in China for Pediatric Leukemia Patients

publication date: May 4, 2022

BeiGene announced China approval for Blincyto® (blinatumomab) to treat pediatric patients with leukemia. In 2020, China’s NMPA approved Blincyto® for adult leukemia patients. BeiGene acquired rights to the candidate from Amgen as part of a $2.7 billion deal signed in 2019 that included China rights to 23 Amgen oncology drugs. BeiGene is responsible for developing the drugs in China (many of them pre-clinical), and Amgen acquired a 20% stake in BeiGene. In its latest approval, Blincyto® is indicated in China to treat pediatric patients with relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia. More details....

Stock Symbols: (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) (NSDQ: AMGN)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here